

TITLE PAGE

Cohort study of fever neonates with confirmed community infection of SARS-CoV-2 Omicron: A study Protocol

^{1,2}Jicheng Li, ^{1,2}Wenwen He, ^{1,2}Yujie Qi, ^{2,3}Yao Meng, ^{2,4}Xiaoxia Peng, ^{1,2}Mingyan
Hei (ORCID 0000-0001-5810-605X)

¹Neonatal Center, Beijing Children's Hospital, Capital Medical University, Beijing,
China

²National Center for Children's Health, Beijing, China

³Department of Clinical Pharmacy, Beijing Children's Hospital, Capital Medical
University, Beijing, China

⁴Center for Clinical Epidemiology and Evidence-based Medicine, Beijing Children's
Hospital, Capital Medical University, Beijing, China

Running title: Cohort study of neonatal COVID

Corresponding authors:

Prof. Mingyan Hei, M.D., Ph.D.

Neonatal Center

Beijing Children's Hospital, Capital Medical University, National Center of
Children's Health

Nanlishi Road 56, Xicheng District

Beijing, 100045, China

Tel: 86-13370179319 (MP), 86-10-59616745 (O)

E-mail: heimingyan@bch.com.cn

28 **Funding:** National Key Research and Development Program of China
29 (#2022YFC2704805) (issued to Dr. Mingyan Hei)

30

31 **Registration:** This study was registered in the China Clinical Trial Registration
32 Center (<http://www.chictr.org.cn>) (ChiCTR2200067148) on December 28, 2022.

33

34 **Word count:** 2418 words (including Main text, Abstract and Strengths and
35 limitations)

36

37 **Abbreviations:**

38	CDC	Centers for Disease Control
39	COVID	coronavirus disease
40	DQ	development quotient
41	IRB	Institutional Ethics Review Board
42	NICU	neonatal intensive care unit
43	OPD	out-patient department

44

45 **[Abstract]** (300 words)

46 **Introduction** Reports on neonatal coronavirus disease (COVID) have been
47 focused on vertical transmission. There was little information on prevalence of
48 neonates with COVID till up to 18 months of age. It is well known that breastfeeding
49 is beneficial for the growth and development of infants. We hypothesized that
50 breastfeeding will be beneficial for a better prevalence of neonatal COVID. The
51 objective of this study is to explore the prognosis of fever neonates with confirmed
52 community infection of SARS-CoV-2 Omicron, and to clarify whether human milk
53 breastfeeding is beneficial for reducing the rate of severe SARS-CoV-2 Omicron
54 infection in neonates.

55 **Methods and analysis** This is a prospective single centre cohort study. Study
56 period is from December, 2022 to December 2024. Inclusion criteria are: (1) Age \leq 28

days or corrected age ≤ 44 weeks. (2) Fever. (3) Both tests (throat swab) of nucleic acid and antigen of SARS-CoV-2 Omicron were positive. (4) Parents signed the consents. Exclusion criteria is confirmed brain malformations. Patients will be classified into breastfeeding, mixed feeding, and formula feeding groups. The estimate sample size will be 200. The throat swab of infants will be collected for SARS-CoV-2 omicron nucleic acid and antigen examination. Neonatal COVID patients will be treated in the Out-Patient Department or admitted to Neonatal Intensive Care Unit according to the severity of infection. All patients will be followed at 3/6/12/18M of age. The endpoint to study was at 18 months of age. Data will be collected by Case Record Form and Electronic Data Capture from the History of In-hospital System. The primary outcome was the rate of severe SARS-CoV-2 infection. *SPSS 20.0* software will be used for statistical analysis.

Ethics and dissemination It is approved by local Institute of Ethics Review Board ([2022]-E-240-Y).

Registration It is registered in the Chinese Clinical Trial Registry (<http://www.chictr.org.cn>) (ChiCTR2200067148)

Key words: Infants, newborn; Fever; Community infection; SARS-CoV-2; Omicron

Strengths and limitations of this study (65 words)

1. This is a prospective single centre cohort study for fever neonates with confirmed community infection of SARS-CoV-2 Omicron.
2. Patients are categorized into breastfeeding group, mixed feeding group, and formula group.
3. The primary outcome is rate of severe SARS-CoV-2 infection.
4. The secondary outcomes include in-hospital outcomes and follow-up outcomes at 3M/6M/12M/18M.
5. Limitations are the observational nature and the single centre data.

86 [Main text] (2053 words)

87 Introduction

88 The global pandemic outbreak of coronavirus disease (COVID) was started in
89 2019. Till now, the number of neonatal COVID has been relatively less than adults.
90 Reports on neonates have been focused on perinatal vertical transmission^{[1][2]}, as well
91 as the safety issues of breastfeeding for neonates^[3]. There were a few publications
92 reported the late onset of infection of SARS-CoV-2 in neonates^{[4][5]}, among which,
93 neonates presented mild fever, mild sniff nose or running nose, or even asymptomatic.
94 The latest report from Shanghai China was published in *Chinese Pediatric Journal* in
95 December 2022, in which 16 COVID neonates were included, and the clinical
96 characteristics and discharge outcomes were described^[6]. However, in the report there
97 were only 11 neonates presented fever and the highest temperature was 38.4°C. So far,
98 there was little information reported on the prevalence of neonates with confirmed
99 community infection of SARS-CoV-2 between birth to 18 months of age.

100 SARS-CoV-2 is easy to have variant strains, causing its contagiousity and
101 pathogenicity variable^[7]. In December 2022, there were a large amount of population
102 infected with SARS-CoV-2 in Beijing, and the strain was Omicron BF7 according to
103 the surveillance by Chinese Centers for Disease Control (CDC)^[8]. Most people were
104 community infected and presented with high fever, severe sore throat, fatigue, body
105 ache, and coughing. Meanwhile, there was a sharply increased number of community
106 infected neonatal patients. High fever, crying, and poor feeding were the commonest
107 symptoms of newborn COVID patients in Beijing during this period, some of the
108 newborns need to be admitted to hospitals. Due to limited information about the
109 community infection of SARS-CoV-2 Omicron in neonates who have apparent
110 infection symptoms, both medical professionals and parents wanted to know: Whether
111 the SARS-CoV-2 Omicron infection at neonatal period will cause negative influence
112 to the infants' growth and development? Is there any protective factor which may
113 reduce the rate of severe SARS-CoV-2 Omicron cases?

114 It is well known that breastfeeding is beneficial for the growth and development
115 of infants. We hypothesized that breastfeeding will be beneficial for a better
116 prevalence from birth to 18 months old when newborns get infected with
117 SARS-CoV-2. The objective of this study is to explore the prognosis of fever
118 neonates with confirmed community infection of SARS-CoV-2 Omicron, and to
119 clarify whether human milk breastfeeding is beneficial to reduce the rate of severe
120 SARS-CoV-2 Omicron infection in neonates.

121

122 **Methods and analysis**

123 *Study design*

124 This is a prospective single centre cohort study.

125

126 *Settings and Participants*

127 The study will be completed in Neonatal Center, Beijing Children's Hospital,
128 Capital Medical University, Beijing, China. The study period is from December 25,
129 2022 to December 31, 2024. Patients diagnosed from December 2022 to May 2023
130 will be approached. All enrolled patients will be followed up from December 2022 to
131 December 2023. The endpoint of study is 18 months of age.

132 Infants who meet all of the following 5 points will be included: (1) Infants who
133 went to Beijing Children's Hospital between December, 2022 to May, 2023. (2) Age
134 ≤ 28 days or corrected age ≤ 44 weeks. (3) Fever. (4) Both tests (throat swab) of
135 nucleic acid and antigen of SARS-CoV-2 Omicron were positive. (5) Parents signed
136 the consents.

137 Infants who had confirmed brain malformations will be excluded.

138 All enrolled patients will be categorized into 3 groups according to their previous
139 feeding: Breastfeeding group, mixed feeding group, formula group.

140

141 *Sample size*

Approximately 200 neonatal patients of SARS-CoV-2 Omicron infection will be enrolled, with a minimal patient number of 30 in each of the three groups. Technically, all patients who meet the inclusion and exclusion criteria in our hospital between December 25, 2022 to May 30, 2024 will be approached, so that the last patient enrolled can finish his/her 18M follow-up in the Out-patient Clinic.

Variables

The primary outcome is rate of severe SARS-CoV-2 infection.

The secondary outcomes are in-hospital outcomes (rate of negative nucleic acid test of SARS-CoV-2 on day 7, time of negative nucleic acid test of SARS-CoV-2, time of negative antigen test of SARS-CoV-2, persistent time of fever, length of stay in NICU, medical expenses, mortality rate) and follow-up outcomes after discharge home (weight/head circumference/height at 3M/6M/12M/18M, development quotient (DQ) at 3M/6M/12M/18M, head magnetic resonance imaging at 3M/12M).

The potential confounders are male gender, age of onset, and number of family members with confirmed COVID meanwhile.

Definitions

Fever refers to the rectal temperature is $\geq 38^{\circ}\text{C}$ ^{[9][10]}.

Community infection of SARS-CoV-2 Omicron of neonates refers to the neonate who meet the following criteria: (1) His/her age is older than 7 days, and (2) home care, and (3) his/her throat swab examination of both nucleic acid and antigen of SARS-CoV-2 Omicron are positive, and (4) more than 1 family members have been confirmed to be COVID patient meanwhile.

Severe case of neonatal SARS-CoV-2 Omicron infection refers to neonates who meet one of the following criteria^{[4][5][11]}: (1) Requiring invasive or non-invasive ventilation, or (2) symptoms and signs of septic shock (such as cyanosis or mosaic on skin, lethargy, cold extremities, no eating), or (3) convulsion, or (4) cyanosis with shallow breathing/breathing difficulty/grunting/apnea, or (5) evidences of bone

171 marrow arrest (severe anemia, and/or white blood cell counting $<3000 \times 10^9/L$, and/or
172 platelet counting $<100 \times 10^{12}/L$), or (6) severe stress hyperglycemia.

173 Breastfeeding refers to the infants' only food is his/her mother's breast milk
174 (either fed by bottle or by putting on the breasts) and has never been fed with any
175 formula.

176 Mixed feeding refers to the infants are fed by his/her mother's own breast milk
177 and formula.

178

179 ***Clinical management of SARS-CoV-2 Omicron infection in neonates***

180 Patients will be diagnosed and managed by neonatologists at Pediatric
181 Out-Patient Department (OPD) or by pediatricians at Emergency Department of
182 Beijing Children's Hospital. Patients will be treated and managed either in OPD or
183 being admitted to NICU, mainly according to patients' severity. All patients will
184 complete the throat swab examination of both nucleic acid and antigen of
185 SARS-CoV-2 Omicron at OPD.

186 Indications for OPD management are: (1) The patient's symptom is only mild
187 fever and persists for less than 24h hours, and (2) his/her general condition is good
188 and feeding is normal, and (3) Whole blood counting and C-reaction protein are
189 normal, and (4) parents are confident to take care of the infant. OPD treatments are
190 mainly physical methods of decreasing body temperature (such as bathing, massage,
191 mild cooling). Parents will be educated to observe the infants' general condition and
192 skin color, as well as extra-supplementation of water feeding during fever.

193 Indications of being admitted to NICU are: (1) Confirmed or suspected severe
194 case of neonatal SARS-CoV-2 Omicron infection, or (2) Higher fever (body
195 temperature $\geq 39^\circ C$), especially persisted for longer than 24 hours, or (3) Infants
196 presents recurrent vomiting or diarrhea. Patients will be kept in isolation area.
197 Treatments in NICU are mainly physical methods of decreasing body temperature,
198 nursing and vital signs monitoring, bottle feeding (according to parents' own decision
199 whether to continue feed with his/her mother's own milk or formula. Parents need to

sign a consent for formula feeding). Enteral feeding is encouraged, but intravenous fluid will be given according to patient's condition in order to maintain a balanced body fluid in/out. On day 5 after admission, throat swab examination of both nucleic acid and antigen of SARS-CoV-2 Omicron will be repeated every 2 days (in a 24-hour-interval). Other clinical managements are adjustable in an individualized principal.

Discharge criteria are: (1) The infants' general condition is good, and meet the general discharge criteria for newborns (including vital signs have been stable and body temperature has been normal for more than 24 hours, and well tolerate enteral feeding)^[11]. (2) Parents are confident to take care of the infants^[12]. (3) There is at least 1 negative result of nucleic acid examination of SARS-CoV-2 Omicron.

After discharge, all patients will be followed in the follow-up clinic at 3M, 6M, 12M and 18 M of age by pediatricians. Growth assessment of weight/head circumference/height will be recorded, as well as the developmental assessment by either Bayley assessment or other development assessment tools.

215

216 ***Examination of SARS-CoV-2 Omicron***

Registered nurses will be in charge of the throat swab and blood collection, and neonatologists will be in charge of cerebral spinal fluid (if needed). All samples will be sent to the virus lab for nucleic acid examination of SARS-CoV-2 Omicron by PCR method within 2 hours. The antigen examination of SARS-CoV-2 Omicron will be completed according to the kit instruction by aerosol method right after the throat swab was collected.

The positive result of nucleic acid examination will be judged only after 2 times of nucleic acid examination were both positive (one kit is from *Da-an Company*, and another kit is from *Zhuo-cheng-hui-sheng Company*, Beijing, China). The positive result of antigen examination of SARS-CoV-2 Omicron is 2 bands on the cartridge within 15 minutes (*Lot.#20223400365*) (the kit is from *Zhong-yuan-hui-ji Ltd. Company*, Chongqing, China).

229

230 ***Data source and measurements***

231 A designated researcher will be assigned to collect and manage the data by using
232 2 methods: (1) Case Record Form (CRF), and (2) Electronic Data Capture (EDC)
233 from the History of In-hospital System (HIS).

234 Demographic data (gestational age, weight, gender, maternal disease, feeding,
235 admission weight, discharge weight) and baseline data of disease (age at onset, body
236 temperature on admission, respiratory symptoms, whole blood count, blood culture,
237 CSF examination, nucleic acid test of SARS-CoV-2 on admission, antigen test of
238 SARS-CoV-2 on admission) will be collected.

239

240 ***Statistical analysis***

241 The Shapiro-Wilk test was firstly used to explore whether the data were normally
242 distributed. Data with normal distribution were expressed as (mean \pm standard
243 deviation), while data with non-normal distribution were expressed as medium (IQR:
244 Q25-Q75). Two-sample *t* tests or rank sum tests were used to compare the continuous
245 variables (e.g., changes in birth weight) for two independent variables. The *chi-square*
246 test was used to compare dichotomous variables. To further compare the rate of
247 severe SARS-CoV-2 infection between groups, we used a generalized linear model to
248 adjust for potential confounders identified from descriptive comparisons of baseline
249 characteristics. Subgroup analysis was also performed. The potential confounders
250 included male gender, number of family members with confirmed COVID
251 meanwhile. Tests with values of $P < 0.05$ were considered significant. There will be
252 no sensitivity analysis. Statistical analyses will be performed using *IBM SPSS 20.0*
253 software (version 26); the figure will be drawn using GraphPad Prism (version 9).

254

255 **Monitoring and Evaluation of the Study**

256 The aim of monitoring and evaluation is to reduce the bias of the study. The
257 major bias is the selective bias due to the nature of single centre cohort study. The
258 monitoring and evaluation of the study are composed of the following 3 sections:

259 ***Monitoring of research process***

260 A designated research coordinator will be in charge of coordinating the research
261 process including interacting with different departments to ensure program
262 implementation and data collection. The principal investigator will summarize the
263 collected data, analyze the data, find problems and make decisions regarding how to
264 solve the problems.

265

266 ***Quality control procedures***

267 The quality control procedures include: (1) Carefully train participating
268 researchers in the study before enrolling patients. (2) To designate a full-time research
269 coordinator to oversee project, and to designated full time graduate students to collect
270 the data. (3) PI will routinely work on the analysis of enrollment and completion
271 numbers and feedback from participating researchers, work with statistical specialists
272 and discuss about the progress of the study.

273

274 ***Procedures to ensure compliance with ethical standards***

275 The procedures include: (1) To obtain ethic approval from the Ethics Committee
276 for Clinical Research in Beijing Children's Hospital. (2) To obtain informed consent
277 from each participating parent before joining the study. (3) To setup a system for
278 incidence reporting, including the use of time limitations (less than 24 hours) and the
279 need for a formal written report. (4) To carefully conduct the study based on
280 procedure in the protocol. (5) To use patient numbers instead of patient names when
281 summarizing the data. (6) To get parents' written approval if their names and pictures
282 are going to appear on the research final report or publications. (7) Respect parents'
283 decision to join or leave the study at any time they wish.

284

285 **Ethics and dissemination**

286 The study was approved by the Institute of Ethics Review Board (IRB) of Beijing
287 Children's Hospital ([2022]-E-240-Y). Data will be deposit in both Department of
288 Neonatology and the Institutional Review Board, which will not be shared with
289 public. Results will be disseminated by publications as soon as possible.

290

291 **Author Contributions**

292 (I) Conception and design: JL, PX, MH; (II) Administrative support: MH; (III)
293 Provision of study materials or patients: JL, WH, YM, YQ; (IV) Collection and
294 assembly of data: JL, WH, YM, YQ, MY; (V) Data analysis and interpretation: JL,
295 WH, YQ, PX, MY; (VI) Manuscript writing: All authors; (VII) Final approval of
296 manuscript: All authors.

297

298 **Funding statement**

299 This work was supported by National Key Research and Development Program
300 of China (#2022YFC2704805) (issued to Dr. Mingyan Hei).

301

302 **Competing interests statement**

303 Nil

304

305 **References**

- 306 [1] Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, Li J, Zhao D, Xu D, Gong Q,
307 Liao J, Yang H, Hou W, Zhang Y. Clinical characteristics and intrauterine vertical
308 transmission potential of COVID-19 infection in nine pregnant women: a
309 retrospective review of medical records[J]. *Lancet*, 2020.
310 [https://doi.org/10.1016/S0140-6736\(20\)30360-3](https://doi.org/10.1016/S0140-6736(20)30360-3)
311 [2] Zhu H, Wang L, Fang C, Peng S, Zhang L, Chang G, Xia S, Zhou W. Clinical

analysis of 10 neonates born to mothers with 2019-nCoV pneumonia[J]. *Transl*
Pediatr 2020;9(1):51-60 | <http://dx.doi.org/10.21037/tp.2020.02.06>

[3] Peng S, Zhu H, Yang L, Cao L, Huang X, Dynes M, Naraya A, Xia J, Chen Y,
Zhang P, Liu H, Li H, Xia S. A study of breastfeeding practices, SARS-CoV-2 and its
antibodies in the breast milk of mothers confirmed with COVID-19[J]. *Lancet*
Regional Health – Western Pacific, 2020.
<https://doi.org/10.1016/j.lanwpc.2020.100045>

[4] Akin IM, Kanburoglu MK, Tayman C, et al. Epidemiologic and clinical
characteristics of neonates with late-onset COVID-19: 1-year data of Turkish
Neonatal Society. *Eur J Pediatr*. 2022;181(5):1933-1942.
<http://doi:10.1007/s00431-021-04358-8>

[5] Sankaran D, Nakra N, Cheema R, Blumberg D, Lakshminrusimha S. Perinatal
SARS-CoV-2 Infection and Neonatal COVID-19: A 2021 Update. *Neoreviews*.
2021;22(5):e284-e295. <http://doi:10.1542/neo.22-5-e1001>

[6] Zhang K, Jiang S, Yan K, Zhang p, Gao R, Zhao J, et al. [Clinical characteristics
of 16 cases of neonatal COVID Omicron variant strain infection]. (in Chinese) *Chin*
Pediatr J, 2022,60(11):1158-1162 <http://doi:10.1007/s00431-021-04358-8>

[7] Wolf JM, Wolf LM, Bello GL, Maccari JG, Nasi LA. Molecular evolution of
SARS-CoV-2 from December 2019 to August 2022. *J Med Virol*. 2022

[8] <http://news.cctv.com/2022/11/28/ARTI0CjqP729lsfFqL3AbGYj221128.shtml>

[9] Hui C, Neto G, Tsertsvadze A, et al. Diagnosis and Management of Febrile Infants
(0-3 months). Evidence Report/Technology Assessment No. 205 (Prepared by the
University of Ottawa: Evidence-based Practice Center under Contract No. HHSA
290-2007-10059-I). AHRQ Publication No. 12-E004-EF. Rockville, MD: Agency for
Healthcare Research and Quality. March 2012. Available at
<http://www.ahrq.gov/research/findings/evidence-based-reports/febrinftp.html>

[10] Up-to-date.
<https://www.uptodate.cn/contents/zh-Hans/the-febrile-infant-younger-than-90-days-of-age-definition-of-fever?search>

- 341 [11] Raschetti R, Vivanti AJ, Vauloup-Fellous C, Loi B, Benachi A, De Luca D.
 342 Synthesis and systematic review of reported neonatal SARS-CoV-2 infections. *Nat*
 343 *Commun.* 2020;11(1):5164. <http://doi.10.1038/s41467-020-18982-9>
 344 [12] Fierman AH. Foreword. Neonatal intensive care unit preparedness for the novel
 345 Coronavirus Disease-2019 pandemic: A New York City hospital perspective. *Curr*
 346 *Probl Pediatr Adolesc Health Care.* 2020;50(4):100801
 347 <http://doi:10.1016/j.cppeds.2020.100801>